Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.69 |
| ▸ | PRKCG | P05129 | 1/20 | 0.69 |
| ▸ | PRKCB | P05771 | 1/20 | 0.69 |
| ▸ | PRKCA | P17252 | 1/20 | 0.69 |
| ▸ | PRKCH | P24723 | 1/20 | 0.69 |
| ▸ | PRKCI | P41743 | 1/20 | 0.69 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.69 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.69 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.69 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.69 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | GMNN | O75496 | 1/20 | 0.69 |
| ▸ | BLM | P54132 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8008187 | 0.99 | AKT1 (0.71) | AKT1LMNAALDH1A1SMN1; SMN2PRKD3 | |
| SCHEMBL8009671 | 0.99 | AKT1 (0.71) | AKT1LMNAALDH1A1SMN1; SMN2PRKD3 | |
| SCHEMBL8007906 | 0.99 | AKT1 (0.71) | AKT1LMNAALDH1A1SMN1; SMN2PRKD3 | |
| SCHEMBL2734470 | 0.99 | AKT1 (0.71) | AKT1LMNAALDH1A1SMN1; SMN2PRKD3 | |
| SCHEMBL7950243 | 0.99 | AKT1 (0.71) | AKT1LMNAALDH1A1SMN1; SMN2PRKD3 | |
| SCHEMBL8643482 | 0.99 | AKT1 (0.71) | AKT1LMNAALDH1A1SMN1; SMN2PRKD3 | |
| SCHEMBL2734284 | 0.99 | AKT1 (0.71) | AKT1LMNAALDH1A1SMN1; SMN2PRKD3 | |
| SCHEMBL8642035 | 0.99 | AKT1 (0.71) | AKT1LMNAALDH1A1SMN1; SMN2PRKD3 | |
| SCHEMBL7645611 | 0.99 | AKT1 (0.71) | AKT1LMNAALDH1A1SMN1; SMN2PRKD3 | |
| SCHEMBL5711833 | 0.92 | ALDH1A1 (0.65) | AKT1LMNAALDH1A1SMN1; SMN2PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118308282-A | Recombinant engineering bacterium for synthesizing citicoline from head by taking glucose as substrate, preparation method and application | 山东金城生物药业有限公司 | 2024-07-09 | — | — | CN | disclosed |
| WO-2023220387-A2 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-10000770-B2 | Methods of expressing products in mammalian cells | INTREXON CEU, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| EP-2861727-B1 | MUTANT ACYL-COA:LYSOPHOSPHATIDYLCHOLINE ACYLTRANSFERASES | DU PONT (US) | 2018-03-21 | — | — | EP | disclosed |
| EP-2935601-B1 | RECOMBINANT MICROBIAL CELLS THAT PRODUCE AT LEAST 28% EICOSAPENTAENOIC ACID AS DRY CELL WEIGHT | DU PONT (US) | 2018-03-21 | — | — | EP | disclosed |
| EP-2443248-B1 | IMPROVEMENT OF LONG CHAIN OMEGA-3 AND OMEGA-6 POLYUNSATURATED FATTY ACID BIOSYNTHESIS BY EXPRESSION OF ACYL-CoA LYSOPHOSPHOLIPID ACYLTRANSFERASES | DU PONT (US) | 2017-12-27 | — | — | EP | disclosed |
| EP-2861728-B1 | IMPROVED PRODUCTION OF POLYUNSATURATED FATTY ACIDS BY COEXPRESSION OF ACYL-COA: LYSOPHOSPHATIDYLCHOLINE ACYLTRANSFERASES AND PHOSPHOLIPID: DIACYLGLYCEROL ACYLTRANSFERASES | DU PONT (US) | 2017-12-27 | — | — | EP | disclosed |
| EP-2935591-B1 | DOWN-REGULATION OF A POLYNUCLEOTIDE ENCODING A SOU2 SORBITOL UTILIZATION PROTEIN TO MODIFY LIPID PRODUCTION IN MICROBIAL CELLS | DU PONT (US) | 2017-07-05 | — | — | EP | disclosed |
| EP-2401696-B1 | MAMMALIAN CELL LINE MODELS AND RELATED METHODS | INTREXON CEU INC (US) | 2017-06-21 | — | — | EP | disclosed |
| US-20160364520-A1 | MAMMALIAN CELL LINE MODELS AND RELATED METHODS | GENOMATICA, INC. | 2016-12-15 | — | — | US | disclosed |
| US-20120185226-A1 | MAMMALIAN CELL LINE MODELS AND RELATED METHODS | GENOMATICA, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| EP-2475679-A1 | IMPROVED OPTIMIZED STRAINS OF YARROWIA LIPOLYTICA FOR HIGH EICOSAPENTAENOIC ACID PRODUCTION | E. I. du Pont de Nemours and Company (US) | 2012-07-18 | — | — | EP | disclosed |
| EP-2443248-A1 | IMPROVEMENT OF LONG CHAIN OMEGA-3 AND OMEGA-6 POLYUNSATURATED FATTY ACID BIOSYNTHESIS BY EXPRESSION OF ACYL-CoA LYSOPHOSPHOLIPID ACYLTRANSFERASES | E. I. du Pont de Nemours and Company (US) | 2012-04-25 | — | — | EP | disclosed |
| EP-2442666-A1 | HIGH EICOSAPENTAENOIC ACID OILS FROM IMPROVED OPTIMIZED STRAINS OF YARROWIA LIPOLYTICA | E. I. du Pont de Nemours and Company (US) | 2012-04-25 | — | — | EP | disclosed |
| US-20110246081-A1 | Metabolomics-Based Identification of Disease-Causing Agents | GEORGIA TECH RESEARCH CORPORATION (US) | 2011-10-06 | — | — | US | disclosed |
| WO-2010147900-A1 | IMPROVEMENT OF LONG CHAIN OMEGA-3 AND OMEGA-6 POLYUNSATURATED FATTY ACID BIOSYNTHESIS BY EXPRESSION OF ACYL-CoA LYSOPHOSPHOLIPID ACYLTRANSFERASES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010147907-A1 | HIGH EICOSAPENTAENOIC ACID OILS FROM IMPROVED OPTIMIZED STRAINS OF YARROWIA LIPOLYTICA | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010147904-A1 | IMPROVED OPTIMIZED STRAINS OF YARROWIA LIPOLYTICA FOR HIGH EICOSAPENTAENOIC ACID PRODUCTION | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-12-23 | — | — | WO | disclosed |
| US-20090281065-A1 | Use of Lysophospholipids to Treat Inflammation | KEMIN INDUSTRIES, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| WO-2009052186-A1 | METABOLOMICS-BASED IDENTIFICATION OF DISEASE-CAUSING AGENTS | GEORGIA TECH RESEARCH CORPORATION (US) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281065-A1 | Use of Lysophospholipids to Treat Inflammation | LPCAT1, LPCAT3, LYPLAL1 | AKT1 3179/4885LMNA 483/4885ALDH1A1 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.